Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. G. Corrie, A. Marshall, P. D. Nathan, P. Lorigan, M. Gore, S. Tahir, G. Faust, C. G. Kelly, M. Marples, S. J. Danson, E. Marshall, S. J. Houston, R. E. Board, A. M. Waterston, J. P. Nobes, M. Harries, S. Kumar, A. Goodman, A. Dalgleish, A. Martin-ClavijoS. Westwell, R. Casasola, D. Chao, A. Maraveyas, P. M. Patel, C. H. Ottensmeier, D. Farrugia, A. Humphreys, B. Eccles, G. Young, E. O. Barker, C. Harman, M. Weiss, K. A. Myers, A. Chhabra, S. H. Rodwell, J. A. Dunn, M. R. Middleton

Research output: Contribution to journalArticlepeer-review

Abstract

In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article.

Original languageEnglish
Pages (from-to)2013-2014
Number of pages2
JournalAnnals of Oncology
Volume30
Issue number12
Early online date20 Aug 2019
DOIs
Publication statusPublished - 1 Dec 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial'. Together they form a unique fingerprint.

Cite this